We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers at Salk Institute for Biological Studies ...

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...

DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and ...

Checkpoint inhibitors act as a double-edged sword against cancer. Although they promote potent antitumor responses, they can also cause several adverse effects. This article joins a growing series on ...

The Vera Bradley Foundation Endowed Chair in Breast Cancer Innovation, Professor of Microbiology and Immunology, Director Brown Center for Immuno-Oncology and Vaccine Immunotherapy, The Indiana ...

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...

This is China's first NDA for a domestic CTLA-4 inhibitor and another milestone strengthening sintilimab's leadership position in cancer immunotherapy. Immune checkpoint blockade (ICB) therapy ...

SAN FRANCISCO and SUZHOU, China, Dec. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

A phase II study of neratinib (Nera) in combination with chemotherapy/trastuzumab/pembrolizumab (C/T/P) in HER2 overexpressing gastroesophageal cancers (GECs). This ...

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...